Your browser doesn't support javascript.
loading
Locally recurrent prostate cancer with RB1/TP53 alterations successfully treated by salvage focal brachytherapy: a case report.
Komori, Takahiro; Kosaka, Takeo; Tanaka, Tomoki; Watanabe, Keitaro; Yasumizu, Yota; Mikami, Shuji; Oya, Mototsugu.
Afiliação
  • Komori T; Department of Urology, Keio University School of Medicine Tokyo, Japan.
  • Kosaka T; Department of Urology, Keio University School of Medicine Tokyo, Japan.
  • Tanaka T; Department of Radiology, Keio University School of Medicine Tokyo, Japan.
  • Watanabe K; Department of Urology, Keio University School of Medicine Tokyo, Japan.
  • Yasumizu Y; Department of Urology, Keio University School of Medicine Tokyo, Japan.
  • Mikami S; Department of Pathology, National Hospital Organization Saitama Hospital Tokyo, Japan.
  • Oya M; Department of Urology, Keio University School of Medicine Tokyo, Japan.
Am J Clin Exp Urol ; 11(4): 339-343, 2023.
Article em En | MEDLINE | ID: mdl-37645609
Retinoblastoma transcriptional corepressor 1 (RB1) and tumor protein p53 (TP53) are well-known tumor suppressor genes; their alterations are associated with poor prognosis in human malignancies and quite rare in locally recurrent cases. The patient was a 58-year-old man who was diagnosed with cT1cN0M0 prostate cancer with Gleason score of 3+3=6 and underwent brachytherapy as the initial treatment. Local recurrence was detected in the left lobe of the prostate 154 months later and whole-exome sequencing that was performed at the request of the patient revealed RB1 loss-of-heterozygosity and TP53 p.I162Rfs*27 mutations. He underwent salvage focal brachytherapy with 125I seeds and serum prostate-specific antigen levels has been stabilized without any genitourinary or gastrointestinal toxicity.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article